# Safety and Efficacy of RX-af01 Combined With PD-1 Antibody

> **NCT05576961** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumor
- Immune Checkpoint Inhibitor
- Intestinal Flora

## Interventions

- **DRUG:** RX-af01
- **DRUG:** Mixed bacteria
- **DRUG:** High dose RX-af01

## Key facts

- **NCT ID:** NCT05576961
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-15
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576961, "Safety and Efficacy of RX-af01 Combined With PD-1 Antibody". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05576961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*